SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024. AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrop

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 ("EP4") antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT') ("CRT") for the treatment of rectal cancer. The study has been developed and is

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC in more than 180 sites around the world, spanning over 18 markets in North America, Europe, Asia, and South America. This clinical study evaluates buparlisib (AN2025), an oral pan-PI3K inhibitor, in combination with paclitaxel for the trea

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study "Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN". The study assessed a novel methodology for identifying recurrent or metastatic squamous cell carcinoma of the head and ne

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares ("ADSs"), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS. All of the ADSs were offered by Adlai Nortye. In addition, Nippon Kayaku Co., Ltd., a chemical company headquartered in Japan, acquired a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private place

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear

H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00

Cantor Fitzgerald initiated coverage of Adlai Nortye Ltd. with a rating of Overweight and set a new price target of $30.00

SC 13G - Adlai Nortye Ltd. (0001944552) (Subject)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

S-8 - Adlai Nortye Ltd. (0001944552) (Filer)

20-F - Adlai Nortye Ltd. (0001944552) (Filer)

6-K - Adlai Nortye Ltd. (0001944552) (Filer)

Cantor Fitzgerald analyst Louise Chen reiterates Adlai Nortye (NASDAQ:ANL) with a Overweight.

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNCY) stock increased by 6.09% to $0.69. The company's market cap stands at $26.1 million. Venus Concept (NASDAQ:VERO) stock increased by 5.71% to $1.11. The company's market cap stands at $7.0 million. Gossamer Bio (NASDAQ:GOSS) stock moved upwards by 4.99% to $0.54. The market value of their outstanding shares is at $121.2 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by 4.86% to $5.82. The market value of their outstanding shares is at $185.1 million. Poseida Therapeuti

Gainers Venus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. Adlai Nortye (NASDAQ:ANL) shares moved upwards by 56.64% to $6.72. The market value of their outstanding shares is at $247.9 million. BioCardia (NASDAQ:BCDA) shares moved upwards by 52.57% to $6.66. The market value of their outstanding shares is at $12.1 million. Geron (NASDAQ:GERN) stock rose 22.36% to $4.76. The market value of their outstanding shares is at $2.8 billion. Seelos Therapeutics (NASDAQ:SEEL) stock moved upwards by 14.66% to $1.29. The market value of their outstanding shares is at $3.3 million. Inda

Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday's session following first-quarter results. Lands’ End reported quarterly adjusted loss of 20 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $285.47 million which beat the analyst consensus estimate of $269.82 million, according to data from Benzinga Pro. Lands’ End shares dipped 9.3% to $12.60 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) shares jumped 512% to $2.88 after the company announced orders for cyber-hardened networking technology to be deployed at thr

Gainers Annexon (NASDAQ:ANNX) shares increased by 57.2% to $7.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $665.3 million. Fresh2 Group (NASDAQ:FRES) shares moved upwards by 36.08% to $0.48. The company's market cap stands at $11.8 million. SunLink Health Systems (AMEX:SSY) stock moved upwards by 32.45% to $0.8. The market value of their outstanding shares is at $5.6 million. Adlai Nortye (NASDAQ:ANL) stock moved upwards by 15.96% to $7.12. The market value of their outstanding shares is at $262.7 million. TRACON Pharma (NASDAQ:TCON) shares rose 15.74% to $1.47. The market value of their outstanding shares is at $3.9 million. Kindly MD (NASD

Gainers OneMedNet (NASDAQ:ONMD) shares increased by 52.3% to $2.97 during Wednesday's after-market session. The company's market cap stands at $70.8 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 19.85% to $0.33. The company's market cap stands at $18.0 million. Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 9.69% to $0.21. The market value of their outstanding shares is at $11.6 million. Petros Pharma (NASDAQ:PTPI) shares increased by 8.74% to $0.67. The company's market cap stands at $4.6 million. Cue Health (NASDAQ:HLTH) stock moved upwards by 8.49% to $0.06. The company's market cap stands at $9.5 million. Adlai Nortye (NASDAQ:ANL) stock rose 8.27% to $8.9. The

Adlai Nortye a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Gainers VolitionRX (AMEX:VNRX) shares rose 33.6% to $0.8 during Tuesday's regular session. The market value of their outstanding shares is at $65.7 million. Palisade Bio (NASDAQ:PALI) stock increased by 29.81% to $6.4. The company's market cap stands at $5.4 million. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 24.67% to $0.14. The market value of their outstanding shares is at $5.5 million. Protagenic Therapeutics (NASDAQ:PTIX) shares increased by 23.88% to $1.55. The company's market cap stands at $6.8 million. BIMI Intl Medical (NASDAQ:BIMI) stock moved upwards by 23.21% to $1.38. The market value of their outstanding shares is at $19.3 million. NKGen Biotech (NASDAQ:NKGN)

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of Matterport, Inc. (NASDAQ:MTTR) rose sharply during Monday's session. CoStar Group, Inc. (NASDAQ:CSGP) announced plans to acquire Matterport in a cash and stock transaction valued at $5.50 per share reflecting an estimated $1.6 billion value. Matterport shares climbed 184% to $4.93 on Monday. Here are some other big stocks recording gains in today's session. Graphjet Technology (NASDAQ:GTI) surged 27.6% to $8.61. Graphjet Technology’s Tham Choi Kuen, CFO, announced the decision to resign due to health reasons, effective immediately. Adlai Nortye Ltd. (NASDAQ:ANL) gained 12.1% to